Prescription medicine use and safety during pregnancy in New Zealand – Dr Sarah Donald
For most prescription medicines available on the market, robust safety information about their use during pregnancy is limited because pregnant women are typically excluded from clinical drug trials. International studies have shown increasing use of prescription medicines during pregnancy over recent decades, making post-marketing safety studies focused on pregnant women vitally important. Retrospective cohort studies undertaken using routinely collected health data can be used to assess medicine safety during pregnancy.
In this presentation I will discuss some findings of my recent research into prescription medicine exposure during pregnancy in New Zealand, including the use of specific medicines known to carry increased risk of fetal harm (Category D/X medicines). I will also discuss the use of antidepressants during pregnancy, and highlight some potential safety issues associated with SSRI use.
|Date||Thursday, 7 May 2020|
|Time||1:00pm - 2:00pm|
|Audience||Postgraduate Only,Staff Only|
|Event Category||Health Sciences|
|Department||Women's and Children's Health (Dunedin)|
|Location||Zoom (please email email@example.com for Zoom room)|
|Contact Name||Sarah-Jane Robertson|